US equities
|
MU
$1,097.39
▲+3.03%
NVDA
$230.86
▲+1.09%
SNDK
$1,787.69
▲+2.75%
INTC
$120.00
▼-0.19%
AAPL
$330.32
▼-0.81%
GOOGL
$338.24
▼-1.70%
TSLA
$354.11
▼-0.20%
AMD
$615.73
▲+0.65%
MU
$1,097.39
▲+3.03%
NVDA
$230.86
▲+1.09%
SNDK
$1,787.69
▲+2.75%
INTC
$120.00
▼-0.19%
AAPL
$330.32
▼-0.81%
GOOGL
$338.24
▼-1.70%
TSLA
$354.11
▼-0.20%
AMD
$615.73
▲+0.65%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Provectus Biopharmaceuticals Inc
(OP:
PVCT
)
0.0544
-0.0027 (-4.73%)
Delayed Quote
Updated: 12:43 PM EDT, Oct 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Provectus Biopharmaceuticals Inc
PVCT Stock Earnings: Provectus Reported Results for Q2 2024
↗
August 13, 2024
Provectus just reported results for the second quarter of 2024.
Via
InvestorPlace
PVCT Stock Earnings: Provectus Reported Results for Q1 2024
↗
May 14, 2024
Provectus just reported results for the first quarter of 2024.
Via
InvestorPlace
PVCT Stock Earnings: Provectus Reported Results for Q4 2023
↗
March 28, 2024
Provectus just reported results for the fourth quarter of 2023.
Via
InvestorPlace
Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December
↗
January 17, 2023
On December 14th, the Federal Reserve hiked its key interest rate by 50 basis points. This was the first deceleration in rate hike increases in 2022; between March and November 2022, the interest rate...
Via
Benzinga